Ulrika Axcrona
Papers
1
Total Citations
30
H-Index
1
About
Ulrika Axcrona is a pioneering translational researcher whose work lies at the intersection of cancer immunotherapy and urologic oncology. Her primary research focus is the development of personalized dendritic cell (DC) vaccines for high-risk prostate cancer, aiming to prevent biochemical relapse after radical prostatectomy. Axcrona’s major contribution is her landmark long-term Phase I/II study—the first-in-human trial of an adjuvant DC vaccine for this patient population—which demonstrated the feasibility, safety, and potential efficacy of this personalized approach. With over 30 citations, this influential work has laid critical groundwork for integrating immunotherapy into the post-surgical management of prostate cancer, offering hope for reducing recurrence in patients with aggressive disease. Her research is notable for bridging bench-to-bedside innovation, combining rigorous immunological monitoring with clinical outcomes. Axcrona’s achievements highlight her role as a leader in advancing cancer vaccine strategies, and her work continues to inspire new avenues for harnessing the immune system to combat high-risk malignancies.
Research Focus
Key Achievements
Top Papers
- 1